Deferoxamine mesylate

SKU: orb1226403

Description

An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.Other Indication Approved(In Vitro):Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells.Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs.Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs.Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells.(In Vivo):Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice.Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.

Key Properties

• CAS Number: 138-14-7
• MW: 656.7897
• Purity: >98% (HPLC)
• Formula: C₂₆H₅₂N₆O₁₁S
• SMILES: CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
• Target: Aluminum|Iron
• Solubility: H2O: ≥ 33 mg/mL

Bioactivity

• In Vivo:
  Animal model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model). Dosage: 6.57 μg/per (10 uL of 1 mM). Administration: Drip-on; once daily for 21 days. Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model. Animal model: Male Sprague-Dawley rats (180-200 g). Dosage: 200 mg/kg. Administration: Intraperitoneal injection; daily for 2 weeks. Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
• In Vitro:
  Western blot analysis. Cell line: MEFs cells. Concentration: 1 mM. Incubation time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions). Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions. Western blot analysis. Cell line: HepG2 cells. Concentration: 100 μM. Incubation time: 24 h. Result: Showed a twofold increase of InsR mRNA levels in cells. Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM. Cell Proliferation Assay Cell line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model)). Concentration: 5, 10, 25, 50, 100 μM. Incubation time: 7 days (TAMSCs); 9 days (BMMSCs). Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 μM dose. Apoptosis Analysis Cell line: TAMSCs, BMMSCs. Concentration: 5, 10, 25, 50, 100 μM. Incubation time: 7 days. Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells. Western blot analysis. Cell line: TAMSCs, BMMSCs. Concentration: 10 μM. Incubation time: 3 days. Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs. Cell Autophagy Assay Cell line: SH-SY5Y cells. Concentration: 100 μM. Incubation time: 24 h. Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Desferrioxamine B mesylate | DFOM

Quick Database Links

Gene Symbol

Aluminum|Iron